Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide
Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide comes in 10 pill versions in our database, in 5 strengths, from 3 manufacturers. Check the imprint to tell them apart.
Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide pill images
20 mg / 5 mg / 12.5 mg 2 pills
- C51 Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide 20 mg / 5 mg / 12.5 mg Orange, round, 8 mm Used for high blood pressure
- p 786 Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide 20 mg / 5 mg / 12.5 mg White, round, 10 mm Used for high blood pressure
40 mg / 5 mg / 12.5 mg 2 pills
- C53 Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide 40 mg / 5 mg / 12.5 mg Yellow, round, 10 mm Used for high blood pressure
- p 787 Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide 40 mg / 5 mg / 12.5 mg Pink, round, 10 mm Used for high blood pressure
40 mg / 5 mg / 25 mg 2 pills
- C54 Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide 40 mg / 5 mg / 25 mg Yellow, oval, 15 mm Used for high blood pressure
- p 788 Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide 40 mg / 5 mg / 25 mg White, oval, 15 mm Used for high blood pressure
40 mg / 10 mg / 12.5 mg 2 pills
- C55 Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide 40 mg / 10 mg / 12.5 mg Red, round, 10 mm Used for high blood pressure
- p 789 Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide 40 mg / 10 mg / 12.5 mg Orange, round, 10 mm Used for high blood pressure
40 mg / 10 mg / 25 mg 2 pills
What is Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide used for?
Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide is used for high blood pressure.
- Medicine type
- ARB (blood pressure medicine); calcium channel blocker (blood pressure and heart medicine)
Official uses from the US prescribing label
Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
Limitations of Use
This fixed combination drug is not indicated for the initial therapy of hypertension.
From the FDA-approved label on DailyMed (published Sep 29, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.